natgillin/translations-raw huggingface dataset:
Spinraza contains the active substance nusinersen which belongs to a group of medicines known as antisense oligonucleotides. 
Zdravilo Spinraza vsebuje učinkovino nusinersen, ki pripada skupini zdravil, ki so znana kot protismiselni oligonukleotidi.
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy. 
Zdravilo Spinraza je indicirano za zdravljenje 5q spinalne mišične atrofije.
Of these patients, 6 (33%) in the Spinraza group and 0 (0%) in the sham-control group met the protocol-defined criteria for a motor-milestone responder. 
Od teh bolnikov jih je 6 (33 %) v skupini z zdravilom Spinraza in 0 (0 %) v kontrolni skupini na placebu izpolnjevalo s protokolom opredeljena merila za bolnika, odzivnega z motoričnimi mejniki.
Just prior to administration, remove the plastic cap and insert the syringe needle into the vial through the centre of the over-seal to remove the appropriate volume. 
Tik pred uporabo odstranite plastično zaporko in zabodite iglo brizge v vialo skozi sredino prekrivne zaporke, da boste odstranili ustrezni volumen.
Population PK analyses revealed no apparent correlation between hepatic and renal clinical chemistry markers and inter-subject variability. 
Populacijske farmakokinetične analize niso razkrile očitne korelacije med označevalci klinične kemije jeter in ledvic in variabilnostjo med preiskovanci.
How long to use Spinraza 
Kako dolgo se zdravilo Spinraza uporablja
Study CS11 is an open label extension study for SMA patients who previously participated in the other Spinraza clinical studies. 
Pri študiji CS11 gre za odprto podaljšano študijo za bolnike s SMA, ki so prej sodelovali v drugih kliničnih študijah z zdravilom Spinraza.
A majority of Spinraza treated patients experienced stabilization or improvement in motor function, with the greatest benefit observed in those with earlier treatment initiation. 
Pri večini bolnikov, zdravljenih z zdravilom Spinraza, so opazili stabilizacijo ali izboljšanje motorične funkcije, največjo korist pa so opazili pri bolnikih, pri katerih je bilo zdravljenje uvedeno zgodaj.
Biogen (Denmark) Manufacturing ApS Biogen Allé 1 
Izdelovalec Biogen (Denmark) Manufacturing ApS
Nusinersen is metabolized slowly and predominantly via exonuclease (3'- and 5') -mediated hydrolysis and is not a substrate for, or inhibitor or inducer of CYP450 enzymes. 
Nusinersen se presnavlja počasi, in sicer pretežno s hidrolizo, ki jo posreduje eksonukleaza (3'- in 5'-), in ni substrat, inhibitor ali induktor encimov CYP450.
The immunogenic response to nusinersen was determined in 346 patients with baseline and post-baseline plasma samples evaluated for anti-drug antibodies (ADA). 
Imunogeni odziv na nusinersen so ugotavljali pri 346 bolnikih z izhodiščnimi in poizhodiščnimi vzorci plazme, v katerih so izmerili protitelesa proti zdravilu (anti-drug antibodies - ADA).
The proportion of patients developing clinically manifested SMA was assessed amongst patients who reached the Day 700 visit at the interim analysis (n=16). 
Delež bolnikov, pri katerih se je razvila klinično izražena SMA, so ocenili pri bolnikih, ki so v času vmesne analize imeli pregled na 700. dan (n = 16).
Nusinersen is an antisense oligonucleotide (ASO) which increases the proportion of exon 7 inclusion in survival motor neuron 2 (SMN2) messenger ribonucleic acid (mRNA) transcripts by binding to an intronic splice silencing site (ISS-N1) found in intron 7 of the SMN2 pre-messenger ribonucleic acid (pre-mRNA). 
Nusinersen je protismiselni oligonukleotid (antisense oligonucleotide - ASO), ki zvečuje delež vključitve eksona 7 v kopije informacijske ribonukleinske kisline (messenger RNA - mRNA) za beljakovino preživetja motoričnega nevrona 2 (survival motor neuron 2 - SMN2), tako da se veže na mesto utišanja izrezovanja intronov (intronic splice silencing site - ISS-N1), ki ga najdemo v intronu 7 predinformacijske ribonukleinske kisline (pre-mRNA) SMN2.
Other medicines and Spinraza 
Druga zdravila in zdravilo Spinraza
Survival Event-free survival2 
Preživetje Preživetje brez dogodkov2
If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours, at a temperature that does not exceed 25°C. 
Če ste jih vzeli iz originalne kartonske škatle, celotni skupen čas brez hlajenja ne sme preseči 30 ur pri temperaturi, ki ni višja od 25 °C.
Spinraza is a clear colourless solution for injection. 
Zdravilo Spinraza je bistra, brezbarvna raztopina za injiciranje.
• Hypersensitivity (an allergic or allergic-like reaction that may include swelling of your face, lips or tongue, rash, or itching) 
• preobčutljivost (alergijska ali alergiji podobna reakcija, ki lahko vključuje otekanje obraza,
Spinal muscular atrophy is caused by a shortage of a protein called survival motor neuron (SMN) in the body. 
Spinalno mišično atrofijo povzroča pomanjkanje beljakovine, ki se imenuje beljakovina preživetja motoričnega nevrona (survival motor neuron - SMN) v telesu.
Baseline disease characteristics were generally similar with the exception of an imbalance in the proportion of patients who had ever achieved the ability to stand without support (13% of patients in the Spinraza group and 29% in sham-control) or walk with support (24% of patients in the Spinraza group and 33% in sham-control). 
Izhodiščne značilnosti bolezni so bile na splošno podobne, z izjemo neravnovesja v deležu bolnikov, ki so sploh kdaj dosegli sposobnost stati brez opore (13 % bolnikov v skupini z zdravilom Spinraza in 29 % kontrolnih bolnikov na placebu) ali hoditi z oporo (24 % bolnikov v skupini z zdravilom Spinraza in 33 % kontrolnih bolnikov na placebu).
Figure 3: Change in HINE Motor Milestones versus Study days for Study CS3B (treated and sham-control), CS3A, CS5 and CS11 
Slika 3: Sprememba motoričnih mejnikov HINE v primerjavi s številom dni trajanja študije za študijo CS3B (zdravljeni in kontrolni na placebu), CS3A, CS5 in CS11
Once drawn into the syringe, if the solution is not used within 6 hours, it must be discarded. 
Če raztopine, ki ste jo vsrkali v brizgo, ne porabite v 6 urah, jo morate zavreči.
Store in the original carton in order to protect from light. 
Shranjujte v originalni kartonski škatli za zagotovitev zaščite pred svetlobo.
Read all of this leaflet carefully before you or your child receives this medicine because it contains important information for you. 
Preden prejmete ali preden vaš otrok prejme to zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
Aseptic technique should be used when preparing and administering Spinraza; see instructions for use in section 6.6. 
Spinraza se mora uporabljati aseptično tehniko; glejte navodila za uporabo v poglavju 6.6. 4.3 Kontraindikacije
An additional clinical study, CS7 (EMBRACE) was opened for patients not eligible for participation in Study CS3B or Study CS4 due to screening age or SMN2 copy number. 
Dodatna klinična študija CS7 (EMBRACE) je bila odprta za bolnike, ki niso izpolnjevali meril za sodelovanje v študiji CS3B ali študiji CS4 zaradi starosti ob presejanju ali števila kopij gena za SMN2.
There are no or limited amount of data from the use of nusinersen in pregnant women. 
Podatkov o uporabi nusinersena pri nosečnicah ni oziroma so omejeni.
As of 19 October 2018, 100 AEs of hypersensitivity due to the administration of nusinersen were identified from the clinical trial database. 
19. oktobra 2018 je bilo iz zbirke podatkov kliničnih preskušanj ugotovljenih 100 neželenih učinkov preobčutljivosti zaradi uporabe nusinersena.
Improvements in motor function were observed among patients continuing Spinraza from Study CS3B, as well as those who initiated Spinraza in Study CS11 (Figure 3), with the greatest benefit observed in those with earlier treatment initiation. 
Izboljšanje motorične funkcije so opazili pri bolnikih, ki so nadaljevali zdravljenje z zdravilom Spinraza iz študije CS3B, in pri tistih, pri katerih je bilo zdravljenje z zdravilom Spinraza uvedeno v študiji CS11 (slika 3), največjo korist pa so opazili pri bolnikih, pri katerih je bilo zdravljenje uvedeno zgodaj.
The benefits-and risks of nusinersen treatment in patients with a ventriculoperitoneal shunt are unknown at present and the maintenance of treatment needs to be carefully considered. 
Trenutno so koristi in tveganja zdravljenja z nusinersenom pri bolnikih z ventrikulo peritonealnim spojem neznana in nadaljevanje zdravljenja je treba skrbno pretehtati.
Figure 2: Mean change from baseline in HFMSE score over time at final analysis (ITT)Study CS4 1,2 
Slika 2: Povprečna sprememba rezultata HFMSE od izhodišča v času pri končni analizi (ITT)študija CS4 1,2
The safety assessment of Spinraza was based on two Phase 3 clinical studies in infants (CS3B) and children (CS4) with SMA, together with one Phase 2 study in infants and children with SMA (CS7) and open-label studies including pre-symptomatic infants (CS5) genetically diagnosed with SMA and infants and children with SMA. 
Ocena varnosti zdravila Spinraza temelji na dveh kliničnih študijah 3. faze pri dojenčkih (CS3B) in otrocih (CS4) s SMA, skupaj z eno študijo 2. faze, v katero so bili vključeni dojenčki in otroci s SMA (CS7), in odprtimi študijami, ki so vključevale predsimptomatične dojenčke (CS5), ki so jim genetsko postavili diagnozo SMA, in dojenčke in otroke s SMA.
Some patients were implanted with a ventriculo-peritoneal shunt. 
Nekaterim bolnikom so vstavili ventrikulo-peritonealni spoj.
Ninety-eight of these were considered not or unlikely related to nusinersen. 
98 izmed teh ni povezanih oziroma je povezanost z uporabo nusinersena malo verjetna.
Study CS5 (NURTURE) is an open-label study in pre-symptomatic infants genetically diagnosed with SMA, who were enrolled at 6 weeks of age or younger. 
Študija CS5 (NURTURE) je odprta študija pri predsimptomatičnih dojenčkih z genetsko diagnozo SMA, ki so jih vključili pri 6 tednih starosti ali še prej.
The effect of hepatic or renal insufficiency as covariates could not be thoroughly evaluated in the population PK model given the rarity of patients displaying clinically relevant liver or kidney insufficiencies. 
Učinka insuficience jeter ali ledvic kot sospremenljivk v populacijskem farmakokinetičnem modelu ni bilo mogoče natančno oceniti zaradi malega števila bolnikov, ki kažejo klinično pomembne znake insuficience ledvic ali jeter.
However, individual safety data for the treatment-emergent ADA-positive cases were reviewed, and no AEs of interest were identified. 
Kljub temu so bili posamezni podatki o varnosti za pozitivne primere ADA, ki so jih odkrili med zdravljenjem,
Mean CSF trough concentrations of nusinersen accumulated approximately 1.4- to 3-fold after multiple loading and maintenance doses, and reached a steady state within approximately 24 months. 
Srednje najnižje koncentracije nusinersena v CSF so se po večkratnih začetnih in vzdrževalnih odmerkih nakopičile za približno 1,4- do 3-krat in dosegle stanje dinamičnega ravnovesja v približno 24 mesecih.
Other products that are in the same group of medicines as Spinraza have been shown to affect the cells in the blood which help clotting. 
Za druga zdravila, ki pripadajo isti skupini zdravil kot zdravilo Spinraza, so dokazali, da vplivajo na krvničke, ki pomagajo pri strjevanju krvi.
An improvement in mean CHOP INTEND score over time was observed from baseline to day 1072 (mean change 21.30). 
Izboljševanje povprečnega rezultata CHOP INTEND so skozi čas ugotavljali od izhodišča do 1072. dne (povprečna sprememba 21,30).
Median age of onset of clinical signs and symptoms was 56 days and patients had either 2 SMN2 gene copies (n=17) or 3 SMN2 gene copies (n=2) (SMN2 gene copy number unknown for 1 patient). 
Mediana starost ob nastopu kliničnih znakov in simptomov je bila 56 dni, bolniki pa so imeli bodisi po 2 kopiji gena za SMN2 (n=17) bodisi po 3 kopije gena za SMN2 (n=2) (število kopij gena za SMN2 za 1 bolnika je bilo neznano).
• If you or your child are allergic to nusinersen or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični ali je vaš otrok alergičen na nusinersen ali katero koli sestavino tega zdravila
Post-marketing experience 
Izkušnje iz obdobja trženja zdravila
In patients with decreased consciousness, an evaluation for hydrocephalus should be considered. 
Pri bolnikih z zmanjšano ravnijo zavesti je treba preveriti, ali imajo hidrocefalus.
A maintenance dose should be administered once every 4 months thereafter. 
Nato je treba dati vzdrževalni odmerek enkrat na vsake
The median age at screening was 3 years, and the median age of onset of clinical signs and symptoms of SMA was 11 months. 
mediana starost ob nastopu kliničnih znakov in simptomov SMA pa 11 mesecev.
What you need to know before you or your child are given Spinraza Spinraza must not be given: 
Kaj morate vedeti, preden bodo vam ali vašemu otroku dali zdravilo Spinraza Zdravilo Spinraza se ne sme dati:
The primary endpoint, time to death or respiratory intervention (defined as invasive or non-invasive ventilation for ≥6 hours/day continuously for ≥7 consecutive days OR 
Primarnega končnega opazovanega dogodka, torej časa do smrti ali respiratorne intervencije (ki je bila opredeljena kot invazivna ali neinvazivna ventilacija za ≥ 6 ur/dan neprekinjeno ≥ 7 zaporednih dni ALI traheostomija), ni bilo mogoče oceniti, ker je bilo takšnih dogodkov premalo.
Taken together, there is sufficient evidence to support a casual association between with nusinersen administration and hypersensitivity; and the PI should be updated accordingly. 
Če povzamemo, je torej na voljo dovolj podpornih dokazov za vzročno povezanost med jemanjem nusinersena in preobčutljivostjo, zato je treba posodobiti informacije o zdravilu.
Patients who initiated Spinraza treatment in Study CS11 (n=20) had a median age of 4.0 years (range 3 - 8 years). 
Mediana starosti bolnikov, ki so zdravljenje z zdravilom Spinraza začeli v študiji CS11 (n = 20), je bila 4,0 let (razpon 3-8 let).
There is a risk of side effects occuring after Spinraza is given by a lumbar puncture procedure (see section 3). 
Obstaja tveganje, da se bodo po dajanju zdravila Spinraza s postopkom lumbalne punkcije pojavili neželeni učinki (glejte poglavje 3).
Single- and multiple-dose pharmacokinetics (PK) of nusinersen, administered via intrathecal injection, were determined in paediatric patients diagnosed with SMA. 
Farmakokinetiko enkratnih in večkratnih odmerkov nusinersena, danega z intratekalno injekcijo, so izmerili pri pediatričnih bolnikih z diagnozo SMA.
If clinically indicated, platelet and coagulation laboratory testing is recommended prior to administration of Spinraza. 
Če je klinično indicirano, je pred dajanjem zdravila Spinraza priporočljivo laboratorijsko testiranje trombocitov in koagulacije krvi.
To allow for long term follow up of these patients, at the end of Study CS3B, 89 patients (Spinraza: n=65; sham-control: n=24) enrolled in Study CS11 (SHINE). 
Da bi omogočili dolgoročno sledenje teh bolnikov, je bilo ob zaključku študije CS3B v študijo CS11 (SHINE) vključenih 89 bolnikov (Spinraza: n = 65; kontrolni bolniki na placebu: n = 24).
The majority of patients (88%) have 3 copies of the SMN2 gene (8% have 2 copies, 2% have 4 copies, and 2% have an unknown copy number). 
(88 %) je imela po 3 kopije gena za SMN2 (8 % jih je imelo po 2 kopiji, 2 % po 4 kopije, 2 % pa neznano število kopij).
Autopsy data from patients (n=3) show that nusinersen administered intrathecally is broadly distributed within the CNS achieving therapeutic levels in the target spinal cord tissues. 
Obdukcijski podatki bolnikov (n=3) kažejo, da se intratekalno injicirani nusinersen na široko porazdeli po CŽS in doseže terapevtske koncentracije v tarčnih tkivih hrbtenjače.
MedDRA preferred term Spinraza frequency category, n=84 
Razred pogostnosti pri zdravilu Spinraza, n=84
The primary route of elimination is expected via urinary excretion of nusinersen and its metabolites. 
Pričakujejo, da je primarna pot izločanja nusinersena in njegovih presnovkov z urinom.
Not known (cannot be estimated from the available data) Table 1: Adverse reactions related to lumbar puncture procedure reported in CS4 (later onset SMA) with an incidence at least 5% higher in patients treated with Spinraza than sham-control 
neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov) Preglednica 1: Neželeni učinki, povezani s postopkom lumbalne punkcije, o katerih so poročali v študiji CS4 (začetek SMA v poznejšem obdobju) s pogostnostjo, ki je vsaj za 5 % višja pri bolnikih, zdravljenih z zdravilom Spinraza, kot pri kontrolnih bolnikih na placebu
• Then around day 14, day 28 and day 63 
• nato okrog 14., 28. in 63. dne; • nato enkrat na vsake 4 mesece.
The pharmacokinetics of nusinersen in patients with renal or hepatic impairment has not been studied. 
Farmakokinetike nusinersena pri bolnikih z okvaro ledvic ali jeter niso proučevali.
Spinraza is administered as an intrathecal bolus injection over 1 to 3 minutes, using a spinal anaesthesia needle. 
Zdravilo Spinraza se daje kot intratekalna bolusna injekcija z iglo za spinalno anestezijo, pri čemer injiciranje traja 1 do 3 minute.
At the interim analysis, all 25 patients (2 SMN2 gene copies, n=15; 3 SMN2 gene copies, n=10) were alive without permanent ventilation.. 
V času vmesne analize je bilo živih vseh 25 bolnikov (s po 2 kopijama gena za SMN2, n = 15; s po 3 kopijami gena za SMN2, n = 10), ki niso prejemali trajne ventilacije.
In patients randomized to Spinraza in Study CS3B and including the experience in Study CS11, the median time to death or permanent ventilation was 73 weeks. 
Pri bolnikih, ki so bili v študiji CS3B randomizirani na zdravilo Spinraza, vključno z bolniki z izkušnjami iz študije CS11, je bila mediana časa do smrti ali trajne ventilacije 73 tednov.
What Spinraza is and what it is used for 
Kaj je zdravilo Spinraza in za kaj ga uporabljamo
Other products that are in the same group of medicines as Spinraza have been shown to affect the kidneys. 
Za druga zdravila, ki pripadajo isti skupini zdravil kot zdravilo Spinraza, so dokazali, da vplivajo na ledvice.
Patients with profound hypotonia and respiratory failure at birth, where Spinraza has not been studied, may not experience a clinically meaningful benefit due to severe SMN protein deficiency. 
Bolnikom z močno hipotonijo in odpovedjo dihanja ob rojstvu, pri katerih zdravila Spinraza niso proučevali, zdravilo mogoče ne bo klinično pomembno koristilo zaradi hudega pomanjkanja beljakovine preživetja motoričnega nevrona (survival motor neuron - SMN).
As a precautionary measure, it is preferable to avoid the use of Spinraza during pregnancy. 
Iz previdnostnih razlogov se je uporabi zdravila Spinraza med nosečnostjo bolje izogibati.
Before you or your child are given Spinraza your doctor may decide to do a urine test to check that your or your child's kidneys are working normally. 
Preden vam bodo dali zdravilo Spinraza, se lahko vaš zdravnik odloči, da bo naredil preiskavo urina, s katero bo preveril, če vaše ledvice ali ledvice vašega otroka normalno delujejo.
Biogen France SAS Tél: +33 (0)1 41 37 95 95 
Tél: +33 (0)1 41 37 95 95
Spinraza must not be diluted. 
Zdravila Spinraza ne smete redčiti.
Study CS11 enrolled infantile and later-onset patients including those who had completed studies CS3B, CS4 and CS12. 
V študijo CS11 so bili vključeni bolniki z zgodnjim nastopom bolezni in bolniki, pri katerih se je bolezen razvila pozneje, vključno s tistimi, ki so zaključili sodelovanje v študijah CS3B, CS4 in CS12.
If a maintenance dose is delayed or missed, Spinraza should be administered as soon as possible and dosing continued every 4 months. 
Če je odložen ali izpuščen vzdrževalni odmerek, je treba dati zdravilo Spinraza čimprej in nato nadaljevati z odmerjanjem na 4 mesece.
Reproductive toxicity 
Toksičnost za razmnoževanje
The population PK analysis suggests that race is unlikely to affect the PK of nusinersen. 
Populacijska farmakokinetična analiza kaže, da rasa verjetno ne vpliva na farmakokinetiko nusinersena.
What Spinraza looks like and contents of the pack 
Izgled zdravila Spinraza in vsebina pakiranja
It is preferable to avoid the use of Spinraza during pregnancy and breast-feeding. 
Uporabi zdravila Spinraza se je med nosečnostjo in dojenjem bolje izogibati.
Spinraza contains a small amount of sodium 
Zdravilo Spinraza vsebuje majhno količino natrija
In vitro studies indicated that nusinersen is not an inducer or inhibitor of CYP450-mediated oxidative metabolism and therefore should not interfere with other medicinal products for these metabolic pathways. 
Interakcije In vitro študije so pokazale, da nusinersen ni induktor ali inhibitor oksidativne presnove, posredovane s CYP450, in zato ne bi smel vplivati na druga zdravila, ki sodelujejo v teh presnovnih poteh.
Treatment with Spinraza should only be initiated by a physician with experience in the management of spinal muscular atrophy (SMA). 
Zdravljenje z zdravilom Spinraza sme začeti le zdravnik, ki ima izkušnje z zdravljenjem spinalne mišične atrofije (SMA).
The usual dose of Spinraza is 12 mg. 
Kako se daje zdravilo Spinraza Običajni odmerek zdravila Spinraza je 12 mg.
Baseline disease characteristics were largely similar in the Spinraza treated patients and sham-control patients except that Spinraza treated patients at baseline had a higher percentage compared to sham-control patients of paradoxical breathing (89% vs 66%), pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%) and requirement for respiratory support (26% vs 15%). 
zdravljenih z zdravilom Spinraza, in pri kontrolnih bolnikih na placebu večinoma podobne, s to izjemo, da so imeli bolniki, zdravljeni z zdravilom Spinraza, v izhodišču večji delež paradoksnega dihanja (89 % proti 66 %), pljučnice ali respiratornih simptomov (35 % proti 22 %), težav s požiranjem ali hranjenjem (51 % proti 29 %) in potrebe po podpori dihanja (26 % proti 15 %).
If the vial remains unopened and the solution is not used, it should be returned back to the refrigerator. 
Če viala ostane neodprta in raztopine ne uporabite, jo dajte nazaj v hladilnik.
If a loading dose is delayed or missed Spinraza should be administered as soon as possible, with at least 14 days between doses, and continue dosing at the prescribed frequency. 
Izpuščeni ali odloženi odmerki Če je odložen ali izpuščen začetni odmerek, je treba dati zdravilo Spinraza čimprej, s tem, da naj bo presledek med odmerki vsaj 14 dni, in nato nadaljevati odmerjanje s predpisano pogostnostjo.
Spinraza is used to treat a genetic disease called spinal muscular atrophy (SMA). 
Zdravilo Spinraza se uporablja za zdravljenje genetske bolezni, ki se imenuje spinalna mišična atrofija (SMA).
Among patients older than the WHO defined window for expected age of achievement (95th percentile), 17 of 22 (77%) had achieved walking alone. 
Med bolniki, katerih starost ni v razponu pričakovane starosti za doseganje mejnikov po SZO (95. percentil), je 17 od 22 bolnikov (77 %) osvojilo mejnik samostojne hoje.
What you need to know before you or your child are given Spinraza 3. 
Kaj morate vedeti, preden bodo vam ali vašemu otroku dali zdravilo Spinraza 3.
Of those with observed values at Month 15, a higher proportion of Spinraza treated subjects had improvement (73% vs 41%, respectively) and a lower proportion of Spinraza treated subjects had worsening (23% vs 44%, respectively) in total HFMSE score compared to sham-control. 
Od tistih z ugotovljenimi vrednostmi v 15. mesecu se je celotni rezultat HFMSE izboljšal večjemu deležu bolnikov (73 % proti 41 %) in poslabšal manjšemu deležu bolniku, zdravljenih z zdravilom Spinraza (23% proti 44%) v primerjavi z bolniki, ki so prejemali placebo.
2 Assessed using the Intent to Treat population (Spinraza n=84; Sham-control n=42); data for patients without a Month 15 visit were imputed using the multiple imputation method 
2Ocenjeno z uporabo populacije z namenom zdravljenja (zdravilo Spinraza n=84; kontrola s placebom n=42); podatki za bolnike brez pregleda v 15. mesecu so bili pripisani z metodo večkratne imputacije.
3Least squares mean 
3Povprečje najmanjših kvadratov.
• On the first day of treatment, day 0 
Zdravilo Spinraza se daje: • na prvi dan zdravljenja, dan 0;